Consolidation by SCT may still imply the highest chance of permanent cure in future treatment of R/R AML, however, addition of targeted agents such as menin inhibitors may potentially allow mitigation of treatment intensity on other parameters, e.g. omission of anthracyclines and consequently reduction of short- and long-term cardiac toxicities (Barlogis et al., 2015; Jarfelt et al., 2016). Here, MEN1 is linked to acute myeloid leukemia.